As you can see above, the placebo group participants managed to loose on average 2% of their body weight, while people in the semaglutide group lost significantly more
Be aware that these carry a small risk of euglycaemic diabetic ketoacidosis DPP-4 inhibitors (e.g., sitagliptin, linagliptin), which are generally well tolerated but less effective for weight reduction Metformin , if not already prescribed, remains the first-line oral agent for type 2 diabetes, though it can also cause gastrointestinal upset Insulin therapy , which may be necessary if oral agents and GLP-1 agonists are not tolerated or insufficient, though this carries a risk of hypoglycaemia When discussing alternatives with your GP, consider bringing up: The severity and duration of your symptoms Any dietary or lifestyle modifications you have already tried Your treatment priorities (e.g., cardiovascular protection, convenience) Other medical conditions or medications that may influence treatment choice NICE guidance (NG28) recommends individualised treatment approaches for type 2 diabetes, taking into account patient preferences, comorbidities, and tolerability
However, it is important to distinguish between the medication starting to work and reaching full appetite suppression
a transparent document request with clear guidance is a good sign
